AliveCor v. Apple Inc. — Federal Circuit Appeal Voluntarily Dismissed in 102 Days
AliveCor, Inc. appealed to the Federal Circuit against Apple, Inc. over two ECG arrhythmia-tracking patents — US9420956 and US10159415. The parties jointly agreed to dismiss the proceeding under Fed. R. App. P. 42(b) after just 102 days, with each side bearing its own costs and no merits ruling issued.
AliveCor drops Federal Circuit ECG patent appeal against Apple
AliveCor, Inc., a cardiac monitoring technology company and holder of patents US9420956 and US10159415 covering methods and systems for arrhythmia tracking and scoring, filed an appeal at the Court of Appeals for the Federal Circuit on 2 August 2024 against Apple, Inc. The appeal arose from an infringement action and targeted technology closely associated with the electrocardiogram capabilities embedded in Apple Watch devices.
The proceeding was terminated on 12 November 2024 by a joint order of dismissal under Federal Rule of Appellate Procedure 42(b). The order does not specify whether the dismissal is with or without prejudice — the public record is silent on this point. Each side was directed to bear its own appellate costs, indicating no party was adjudged a winner or loser at this stage.
The 102-day duration from filing to dismissal is notably short for a Federal Circuit appeal, suggesting the parties reached an agreement — whether a settlement, licensing arrangement, or strategic withdrawal — well before any substantive briefing concluded. The underlying reasons are not disclosed in the public docket, and it remains unknown whether the core infringement dispute over the two ECG patents has been resolved or merely paused.
Filing to Voluntary dismissal in 102 days
102 days — notably short for a Federal Circuit appeal, suggesting early resolution
Voluntarily dismissed: what the Rule 42(b) order means for both parties
Fed. R. App. P. 42(b): a consent dismissal, not a merits ruling
Rule 42(b) allows parties to dismiss a Federal Circuit appeal by stipulation. The court issues no opinion on the underlying merits — no finding of infringement, validity, or invalidity is made. This means the lower tribunal’s record stands undisturbed by this order, but equally no appellate precedent is created. The dismissal reflects party agreement, not judicial adjudication.
No merits adjudicationPublic record is silent on prejudice status
A dismissal ‘with prejudice’ bars refiling of the same claims permanently; ‘without prejudice’ preserves the right to refile. Rule 42(b) dismissals may be either, but the order in this case does not specify. AliveCor’s ability to reassert these patents in future proceedings — whether in district court or via ITC — cannot be definitively determined from the public docket alone.
Prejudice status undisclosedAppellant withdraws without a Federal Circuit ruling
AliveCor initiated this appeal and chose to withdraw it. Without a merits ruling, the company gains no appellate vindication of its patent positions on US9420956 or US10159415. The voluntary nature of the dismissal may suggest a negotiated resolution — licensing terms, cross-licensing, or a broader settlement — but none of this is confirmed in the public record.
No appellate vindicationApple avoids Federal Circuit merits exposure on ECG patents
Apple escapes a Federal Circuit ruling that could have adversely interpreted the two AliveCor ECG patents. The cost-neutral outcome and absence of any injunction or damages finding is commercially favourable for Apple Watch’s ECG feature line. However, the patents remain in force and the underlying dispute’s resolution is undisclosed, leaving residual IP risk unquantified.
Residual patent risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AliveCor, Inc. | Company | Cardiac monitoring technology company — holder of US9420956 and US10159415Search in Eureka ↗ |
| Defendant | Apple, Inc. | Company | Apple, Inc. — global consumer electronics manufacturer, maker of Apple Watch with ECG featuresSearch in Eureka ↗ |
| Plaintiff counsel | Joseph Baillargeon | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew A. Argenti | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael T. Rosato | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Tasha Thomas | Attorney | Counsel for AliveCor, Inc.Search in Eureka ↗ |
| Plaintiff law firm | WilsonSonsini Goodrich & Rosati LLP | Law Firm | Representing AliveCor, Inc.Search in Eureka ↗ |
| Defendant counsel | Abigail Colella | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Elizabeth Moulton | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Melanie L. Bostwick | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael Ari Amon | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Walter Karl Renner Esq. | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant counsel | Zachary Hennessee | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | Fish & Richardson PC | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | Orrick, Herrington & Sutcliffe LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order’s operative language — ‘DISMISSED under Fed. R. App. P. 42(b)’ — confirms a consent dismissal with no merits adjudication. The Federal Circuit issued no opinion on infringement, claim construction, or patent validity. The cost-neutrality clause (‘each side shall bear their own costs’) is consistent with a negotiated exit. The absence of any merits ruling means neither party can cite this proceeding as precedent, and the validity and enforceability of US9420956 and US10159415 are unchanged.
US9420956 & US10159415 — ECG arrhythmia tracking and scoring methods
US9420956 (application no. US14/569513) and US10159415 (application no. US15/393077) both fall within AliveCor’s portfolio of ECG-based cardiac monitoring innovations. The patents cover methods and systems for arrhythmia tracking and scoring — technology directly relevant to the real-time atrial fibrillation detection features embedded in wearable devices such as Apple Watch. The application lineage suggests a continuation strategy designed to maintain broad claim coverage across evolving hardware implementations.
These patents sit at the intersection of consumer wearables and clinical-grade cardiac monitoring — a high-value battleground as Apple, Samsung, Fitbit, and emerging medtech players compete to embed diagnostic-quality ECG capabilities into mass-market devices. AliveCor’s enforcement history, including prior ITC proceedings against Apple, suggests an aggressive and sustained licensing strategy. Any company commercialising wearable arrhythmia detection should treat these patents as live enforcement risks requiring current FTO clearance.
Should your team run an FTO against US9420956 and US10159415?
If your organisation is developing or commercialising wearable devices with ECG, arrhythmia detection, or cardiac scoring functionality — including smartwatches, fitness bands, medical-grade patches, or mobile ECG accessories — both AliveCor patents represent active FTO exposure. The voluntary dismissal at the Federal Circuit does not extinguish these patents or narrow their claims. R&D and product teams should conduct a current FTO review before launch or product iteration.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map claim scope across US9420956 and US10159415, identify relevant prior art, and surface continuation or family patents that may extend AliveCor’s coverage. Eureka can also flag pending AliveCor applications that may issue as future enforcement instruments, giving product teams early-warning visibility into the evolving ECG patent landscape.
Run a freedom-to-operate analysis on US9420956 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ECG and wearable cardiac monitoring patent appeals
Cases matching AliveCor v. Apple’s profile: Federal Circuit appeals involving wearable ECG, cardiac arrhythmia detection patents, and consumer electronics defendants.
What this case signals for the wearable ECG and cardiac monitoring IP landscape
A rapid voluntary dismissal at the Federal Circuit in a high-profile ECG patent dispute carries significant signal value for wearables IP strategy.
Rapid Federal Circuit exits often signal a negotiated commercial resolution
A 102-day dismissal — before full appellate briefing — is consistent with parties reaching a licensing or settlement agreement. IP teams monitoring AliveCor or Apple’s ECG patent portfolios should treat this as a potential indicator of ongoing commercial engagement rather than a clean break, and track subsequent licensing disclosures or ITC activity.
ECG arrhythmia patents remain in force and enforceable post-dismissal
Neither US9420956 nor US10159415 has been invalidated or narrowed by this proceeding. Companies developing wearable cardiac monitoring products — particularly those targeting atrial fibrillation detection — should ensure their FTO analysis is current against both patents, as AliveCor retains full enforcement rights.
AliveCor v Apple — key questions answered
AliveCor’s Federal Circuit appeal (Case No. 24-2168) against Apple was voluntarily dismissed under Fed. R. App. P. 42(b) on 12 November 2024, just 102 days after filing. No merits ruling was issued. Each party was ordered to bear its own costs. The underlying infringement dispute concerned ECG arrhythmia-tracking patents US9420956 and US10159415.
AliveCor asserted US9420956 (application US14/569513) and US10159415 (application US15/393077), both covering methods and systems for arrhythmia tracking and scoring. These patents relate to ECG-based cardiac monitoring technology relevant to Apple Watch’s heart rhythm detection features.
A Fed. R. App. P. 42(b) dismissal is a consent-based termination of an appeal. The court issues no opinion on merits — no infringement, validity, or claim construction ruling is made. The dismissal may be with or without prejudice; if unspecified, the prejudice status is ambiguous. The underlying patents remain in force and enforceable.
The public order is silent on this point. The dismissal was entered under Rule 42(b) by agreement, but the order does not explicitly state whether it is with or without prejudice. This ambiguity means AliveCor’s right to reassert its claims in future proceedings cannot be definitively ruled out based on the public record alone.
Yes. The voluntary dismissal does not invalidate, limit, or narrow US9420956 or US10159415. Neither patent was adjudicated in this appeal. Companies developing wearable ECG or arrhythmia detection products should treat both patents as active enforcement risks and ensure current freedom-to-operate clearance before commercialisation.
PatSnap Eureka searches patents and litigation data to answer instantly.